Targeted cancer therapies double the survival chances of patients
CompanyOctober 2018
IndivuTest GmbH, Hamburg, Germany
A proof-of-concept study was conducted to assess whether patients with advanced-stage IV cancer for whom predominantly no standard therapy was available could benefit from comprehensive molecular profiling of their tumor tissue to provide targeted therapy. Tumor samples of 83 patients were collected under highly standardized conditions and analyzed using immunohistochemistry, next-generation sequencing and phosphoprotein profiling. Based on molecular profiling, targeted therapies were decided by the attending oncologist. Accordingly, 28 patients who met the defined criteria fell into two equal-sized groups. One group received targeted therapies while the other did not. Following six months of treatment, disease control was achieved by 49% of patients receiving targeted therapy and 21% of patients receiving non-targeted therapy Individual patients experienced dramatic responses to a therapy that otherwise would not have been applied. This approach clarifies the value of multi-omic molecular profiling for cancer diagnostics.
Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patients
Alexandra Samsen
Added on: 06-21-2021
[1] https://www.oncotarget.com/article/26198/text/
